Latest Biotech News

Anthropic launched a life-sciences–focused model and inked collaborations to let researchers query biological datasets in plain English, signaling Big Tech’s deeper push into drug discovery and...

Industry analysis and company moves underscore a pivot: contract development and manufacturing organizations (CDMOs) are now strategic partners for cell and gene therapy scale-up. Reports stress...

Researchers using single-cell RNA and TCR sequencing in longitudinal mouse tumor models identified a conserved gene expression 'expansion signature' that predicts CD8+ T cell clonal bursts prior...

Researchers reported development of CAR T cells engineered to target antigens associated with HIV-linked B cell malignancies, offering a tailored cell therapy strategy for a distinct subset of...

Private-equity firms Blackstone and TPG agreed to acquire Hologic in a transaction valued at up to $18.3 billion, offering $76 per share plus up to $3 in contingent value rights tied to...

Researchers published an integrated platform that combines targeted epigenetic edits with multiplexed genetic engineering to reprogram primary human T cells, reporting enhanced functional profiles...

Cancer early‑detection company Grail said it has agreed a private placement expected to raise roughly $325 million to support commercial expansion and reimbursement efforts. The financing includes...

The FDA has accepted Replimune’s resubmission for RP1, the company’s oncolytic herpes‑based biologic for advanced melanoma, and set a regulatory decision date of April 10, 2026. Replimune said the...

Exelixis plans an NDA filing for zanzalintinib after detailed STELLAR‑303 data showed an overall survival benefit when combined with Roche’s atezolizumab in previously treated metastatic...

Illumina executives outlined progress on the company’s multiomics strategy at ASHG, saying roadmap technologies will be market‑ready next year as the firm integrates proteomics, single‑cell and...

CRISPR Therapeutics publicly described a new gene‑editing tool as “a significant advance” over prime editing, prompting a rebuttal from Prime Medicine and sparking debate across the gene‑editing...

10x Genomics has filed a lawsuit alleging that Illumina infringes patents covering single‑cell and spatial transcriptomics technologies. The complaint follows a pattern of aggressive IP...

Deal activity in the antibody‑drug conjugate (ADC) space continued as Aimedbio struck a near‑$1 billion licensing agreement with Boehringer Ingelheim for a preclinical solid‑tumor ADC candidate,...

Chugai Pharmaceutical and Rani Therapeutics entered a global license and collaboration to develop an oral product combining Rani’s Ranipill robotic oral delivery technology with Chugai’s...

Galapagos announced plans to wind down its cell therapy business after a search for buyers produced insufficient offers, saying most non‑binding proposals came from financial investors and lacked...

Researchers published a multiplexed platform that combines targeted epigenetic editing with genetic edits to program primary human T cells for enhanced function. The studies, reported in Nature...

Replimune resubmitted data and analyses for its oncolytic virus RP1 in advanced melanoma and the FDA has accepted the filing for a second review, assigning an Apr. 10, 2026 action date. The...

Grail announced a private placement to raise roughly $325 million to fund commercial expansion and reimbursement efforts for its Galleri multi‑cancer early detection test. The financing follows...

Aimedbio signed a license agreement with Boehringer Ingelheim worth up to $991 million to develop and commercialize a preclinical antibody‑drug conjugate targeting solid tumors, including...

Chugai Pharmaceutical struck a global license and collaboration with Rani Therapeutics to develop an oral formulation that pairs Rani’s Ranipill robotic delivery with Chugai’s rare‑disease...